The purpose of this study is to look at the safety and effectiveness of PAXLOVID in the real world and not in clinical studies. The study observes patients who have a high chance of getting severe COVID-19 in Korea. This study is seeking participants who are: * Patients with mild-to-moderate COVID-19 symptoms and at high chance of getting severe COVID-19, including hospitalization or death. * Patients who received, are currently receiving, or are going to receive PAXLOVID according to locally approved label. * Patients who have signed informed consent documents after understanding all the important parts of the study. All participants are treated according to routine medical practice and there are no scheduled visits required by this study. All participants will be studied for a follow-up period of 28 days from the last PAXLOVID treatment to understand the safety and the effectiveness of treatment.
Age range
19 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Proportion of patients with an adverse event (AE)
Timeframe: Baseline through Day 33
Proportion of patients with an adverse drug reaction (ADR)
Timeframe: Baseline through Day 33
Proportion of patients with a serious AE (SAE)
Timeframe: Baseline through Day 33
Proportion of patients with a serious ADR (SADR)
Timeframe: Baseline through Day 33
Proportion of patients with an unexpected AE (UAE)
Timeframe: Baseline through Day 33
Proportion of patients with an unexpected ADR (UADR)
Timeframe: Baseline through Day 33
Proportion of patients with a serious unexpected AE (SUAE)
Timeframe: Baseline through Day 33
Pfizer CT.gov Call Center
Proportion of patients with a serious unexpected ADR (SUADR)
Timeframe: Baseline through Day 33
Proportion of COVID-19-related hospitalization from any cause
Timeframe: Baseline through Day 33
Proportion of COVID-19-related death from any cause
Timeframe: Baseline through Day 33
Proportion of subjective assessment of COVID-19-related symptomatic change
Timeframe: Day 5, Day 14, Day 33